Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management plans to address this uncertainty through a Business Combination. There is no assurance that the Company's plans to raise capital or to consummate a Business Combination will be successful within the Combination Period. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed Aug 14, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
IB Acquisition Corp. has no specific business combination under consideration after redemptions removed approximately $106.1 million from its trust, leaving approximately $15.8 million. Its combination period ends March 28, 2026 unless extended.
IB Acquisition Corp. will hold a virtual annual meeting on December 16, 2026, with 4,890,843 shares outstanding as of the October 28, 2026 record date. Stockholders will vote on four director nominees, MaloneBailey LLP’s appointment, and meeting adjournment authority.
IB Acquisition Corp. will hold its 2026 Annual Meeting on December 16, 2026 at 10:00 a.m. Eastern Time, with October 28, 2026 as the record date. Stockholder proposals are due October 26, 2026, and the meeting is expected to enable Nasdaq Listing Rule 5620(a) compliance.
IB Acquisition Corp. received Nasdaq notice that it failed the annual meeting requirement and has 45 calendar days to submit a compliance plan. Nasdaq may grant an exception until March 29, 2027; common stock will continue trading as IBAC.
IB Acquisition Corp. stockholders approved extending the initial-business-combination deadline from September 28, 2026 to March 28, 2027; 117,386 shares were redeemed at approximately $10.97 per share, leaving approximately $7,042,627.97 in the trust account.
Useful current figures from the complete screener profile.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IBAC
this stock
IB Acquisition Corp.
|
$54.14M | +3.0% | — | — | 0.1% |
|
VYLR
Vylor Inc.
|
$46.80B | — | — | — | 2.2% |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | — | — | — | — |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$650.38M | +3.1% | — | — | 0.0% |
|
CCXI
Churchill Capital Corp XI
|
$627.18M | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
IB Acquisition Corp. has no specific business combination under consideration after redemptions removed approximately $106.1 million from its trust, leaving approximately $15.8 million. Its combination period ends March 28, 2026 unless extended.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IBAC | -0.5% | -1.1% | +1.1% | -0.5% | +3.0% |
| SPY | -1.7% | -2.9% | +1.9% | -0.5% | +10.3% |
| vs SPY | +1.3% | +1.8% | -0.8% | +0.0% | -7.3% |
